Equipment Supplement request for a BD LSR Fortessa Flow Cytometer

BD LSR Fortessa 流式细胞仪的设备补充请求

基本信息

  • 批准号:
    9275190
  • 负责人:
  • 金额:
    $ 12.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-01 至 2020-01-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): This application is submitted under the NIH multiple PI initiative (http://grants.nih.gov/grants/guide/notice- files/NOT-OD-11-118.html). Drs. Ed Sherwood and David Williams with serve as the PIs. The multiple PI strategy is advantageous because it enables a "team science" approach that will draw equally on the expertise and experience of both of the PIs as well as their respective institutions. The critically ill patient frequently develops a complex disease spectrum that may include acute respiratory distress syndrome, systemic inflammatory response syndrome, sepsis syndrome, septic shock and/or multiple organ dysfunction syndrome. In the United States ~951,000 patients/year develop sepsis with approximately half of these patients in the ICU. The overall mortality rate is 28.6%. Those patients that survive the initial septic event may ultimately succumb to widespread organ dysfunction that can be either acute, due to hyper-inflammatory responses, or more prolonged due to immune dysfunction. It is well accepted that sepsis causes suppression of the immune system and that sepsis-induced immunoparalysis predisposes the critically ill patient to secondary infections. Attempts at developing effective therapies to prevent or treat sepsis and its associated immunosuppression have proven to be exceedingly difficult. In fact, no drugs are currently approved by the FDA for the management of sepsis. Recent data have provided compelling evidence that the innate immune system can be "trained" to respond more rapidly and effectively to pathogens following treatment with Dectin-1 agonists. We have successfully synthesized Dectin-1 ligands that increase resistance to sepsis. In this application, we propose the novel concept that it may be possible to "train" the compromised immune system with synthetic Dectin-1 ligands, such that an effective response can be mounted to existing and/or subsequent infections. We hypothesize that "immunologic training and metabolic reprogramming will decrease septic morbidity and mortality in clinically relevant models of sepsis and augment host immunity in vulnerable populations". To critically evaluate this hypothesis, we propose the following specific aims. Aim 1. Determine the effects of immune training on sequelae and outcomes in CLP-induced polymicrobial sepsis. This aim will define the efficacy of immune training in murine model of polymicrobial sepsis. Specifically, this aim wil determine if synthetic Dectin-1 agonists can "train" the immune system to prevent and/or treat polymicrobial sepsis. Aim 2. Determine the effect of immune training on sequelae and outcomes in a clinically relevant model of post-burn immunosuppression. This aim will establish whether training will improve survival in clinically relevant model of post-burn immunosuppression. Aim 3. Establish the impact of training on innate immune parameters in sepsis. This aim will define the alterations in innate immune function by which training augments the host response to infection. Aim 4. Define the mechanisms by which synthetic Dectin-1 ligands induce trained immunity. This aim will define the specific signaling alterations by which immune training enhances antimicrobial responses in populations that are at high risk of developing infections.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EDWARD R SHERWOOD其他文献

EDWARD R SHERWOOD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EDWARD R SHERWOOD', 18)}}的其他基金

Macrophage mitochodrial reprogramming and innate immune memory
巨噬细胞线粒体重编程和先天免疫记忆
  • 批准号:
    10550138
  • 财政年份:
    2020
  • 资助金额:
    $ 12.74万
  • 项目类别:
Macrophage mitochodrial reprogramming and innate immune memory
巨噬细胞线粒体重编程和先天免疫记忆
  • 批准号:
    10333362
  • 财政年份:
    2020
  • 资助金额:
    $ 12.74万
  • 项目类别:
Training Innate Immunity: A new approach to the treatment of Sepsis
训练先天免疫:治疗脓毒症的新方法
  • 批准号:
    10296894
  • 财政年份:
    2016
  • 资助金额:
    $ 12.74万
  • 项目类别:
Training Innate Immunity: A new approach to the treatment of Sepsis
训练先天免疫:治疗脓毒症的新方法
  • 批准号:
    10461115
  • 财政年份:
    2016
  • 资助金额:
    $ 12.74万
  • 项目类别:
Equipment supplement to "Training Innate Immunity: A new approach to the treatment of sepsis"
《训练先天免疫:治疗脓毒症的新方法》的设备补充
  • 批准号:
    10794766
  • 财政年份:
    2016
  • 资助金额:
    $ 12.74万
  • 项目类别:
Training Innate Immunity: A new approach to the treatment of Sepsis
训练先天免疫:治疗脓毒症的新方法
  • 批准号:
    10669060
  • 财政年份:
    2016
  • 资助金额:
    $ 12.74万
  • 项目类别:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
Beta 2 微球蛋白无效小鼠对脓毒症的抵抗力
  • 批准号:
    7256520
  • 财政年份:
    2003
  • 资助金额:
    $ 12.74万
  • 项目类别:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
Beta 2 微球蛋白无效小鼠对脓毒症的抵抗力
  • 批准号:
    7811704
  • 财政年份:
    2003
  • 资助金额:
    $ 12.74万
  • 项目类别:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
Beta 2 微球蛋白无效小鼠对脓毒症的抵抗力
  • 批准号:
    8578744
  • 财政年份:
    2003
  • 资助金额:
    $ 12.74万
  • 项目类别:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
Beta 2 微球蛋白无效小鼠对脓毒症的抵抗力
  • 批准号:
    8292209
  • 财政年份:
    2003
  • 资助金额:
    $ 12.74万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.74万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 12.74万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.74万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.74万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 12.74万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.74万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.74万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.74万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 12.74万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 12.74万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了